Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus

医学 2型糖尿病 糖尿病 内科学 内分泌学
作者
Jason Powell,Scott Garland
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:53 (5): 478-485 被引量:7
标识
DOI:10.1177/1060028018818829
摘要

Objective: The purpose of this article is to review the pharmacological aspects of ertugliflozin and its clinical trials, which led to Food and Drug Administration (FDA) approval for the treatment of type 2 diabetes mellitus (T2DM). Data Sources: A MEDLINE/PubMed (May 2013 to October 2018) search was conducted using the following keywords: ertugliflozin, sodium glucose co-transporter 2 inhibitor, SGLT2 inhibitor, type 2 diabetes mellitus, hyperglycemia. Study Selection and Data Extraction Quantify: We included English-language articles evaluating ertugliflozin pharmacology, pharmacokinetics, efficacy, and safety in humans for blood glucose reduction in human subjects. Data Synthesis: Ertugliflozin has been FDA approved and considered both safe and efficacious for the treatment of T2DM with hemoglobin A 1C reductions ranging from −0.6% to −1.16%. Safety outcomes appear to be similar to that of other SGLT2 inhibitors. Relevance to Patient Care and Clinical Practice: With this approval, patients and clinicians now have another oral option for treating this difficult disease while minimizing hypoglycemia and other unwanted adverse drug reactions. Conclusions: With the number of patients with diabetes growing, additional safe and effective treatment options available for clinicians and patients is important. Ertugliflozin appears to be an effective and safe therapy as both single and add-on therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔应助晴云采纳,获得10
1秒前
快乐小狗完成签到 ,获得积分10
1秒前
珞珈完成签到,获得积分10
1秒前
Ya完成签到,获得积分10
1秒前
谦让文昊完成签到,获得积分10
2秒前
小红勇闯科研界完成签到,获得积分10
4秒前
科研通AI2S应助长安采纳,获得10
6秒前
6秒前
7秒前
Amber完成签到,获得积分10
7秒前
7秒前
teborlee完成签到,获得积分10
8秒前
xinxin完成签到,获得积分10
8秒前
SYLH应助鳗鱼鸽子采纳,获得10
8秒前
YY完成签到,获得积分10
9秒前
老德完成签到,获得积分10
9秒前
靓丽的熠彤完成签到,获得积分10
10秒前
深情海秋完成签到,获得积分10
10秒前
11秒前
歇洛克完成签到,获得积分10
12秒前
cao完成签到,获得积分20
12秒前
为你博弈完成签到,获得积分10
13秒前
13秒前
于情信芳完成签到,获得积分10
13秒前
庚小马发布了新的文献求助10
13秒前
淡然妙竹发布了新的文献求助10
14秒前
炒栗子发布了新的文献求助10
14秒前
晴云发布了新的文献求助10
14秒前
15秒前
PHW完成签到,获得积分10
15秒前
monly应助Fin2046采纳,获得30
16秒前
Hello应助JJG采纳,获得10
16秒前
李健的小迷弟应助WJH采纳,获得10
16秒前
18秒前
ty发布了新的文献求助10
18秒前
刘逸藩完成签到,获得积分10
18秒前
yulian完成签到,获得积分10
19秒前
chemhub完成签到,获得积分10
19秒前
歇洛克发布了新的文献求助10
19秒前
Lee发布了新的文献求助10
19秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048